Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-585 perioperative pembrolizumab plus chemotherapy for resectable gastric or gastroesophageal junction adenocarcinoma
MOH_2017-06-11_000506Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pembrolizumab arm with Placebo arm (2 arms). Planned start Jun 2017; status: not yet recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2017-06-11_000506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-11_000506.